[go: up one dir, main page]

MA53765B2 - Tubulysines et conjugués tubulysines-protéines - Google Patents

Tubulysines et conjugués tubulysines-protéines

Info

Publication number
MA53765B2
MA53765B2 MA53765A MA53765A MA53765B2 MA 53765 B2 MA53765 B2 MA 53765B2 MA 53765 A MA53765 A MA 53765A MA 53765 A MA53765 A MA 53765A MA 53765 B2 MA53765 B2 MA 53765B2
Authority
MA
Morocco
Prior art keywords
tubulysines
tubulysine
conjugués
protéine
antibodies
Prior art date
Application number
MA53765A
Other languages
English (en)
Other versions
MA53765A1 (fr
Inventor
Marcus KELLY
William Olson
Amy Han
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of MA53765A1 publication Critical patent/MA53765A1/fr
Publication of MA53765B2 publication Critical patent/MA53765B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés, des compositions et des méthodes pour le traitement de maladies et de troubles associés au cancer, comprenant des tubulysines et des conjugués médicamenteux protéiques (par ex., anticorps) associés.
MA53765A 2018-12-21 2019-12-20 Tubulysines et conjugués tubulysines-protéines MA53765B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862784325P 2018-12-21 2018-12-21
PCT/US2019/068185 WO2020132658A2 (fr) 2018-12-21 2019-12-20 Tubulysines et conjugués tubulysines-protéines

Publications (2)

Publication Number Publication Date
MA53765A1 MA53765A1 (fr) 2022-02-28
MA53765B2 true MA53765B2 (fr) 2025-04-30

Family

ID=69185739

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53765A MA53765B2 (fr) 2018-12-21 2019-12-20 Tubulysines et conjugués tubulysines-protéines

Country Status (19)

Country Link
US (1) US12144864B2 (fr)
EP (1) EP3898651A2 (fr)
JP (2) JP7590328B2 (fr)
KR (1) KR20210106467A (fr)
CN (2) CN113454097B (fr)
AU (1) AU2019403554B2 (fr)
BR (1) BR112021011729A2 (fr)
CA (1) CA3124106A1 (fr)
CL (2) CL2021001593A1 (fr)
CO (1) CO2021009129A2 (fr)
EA (1) EA202191769A1 (fr)
IL (1) IL283942A (fr)
MA (1) MA53765B2 (fr)
MX (1) MX2021007235A (fr)
MY (1) MY208067A (fr)
PH (1) PH12021551421A1 (fr)
SG (1) SG11202106067UA (fr)
WO (1) WO2020132658A2 (fr)
ZA (1) ZA202103867B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113454097B (zh) 2018-12-21 2024-08-30 里珍纳龙药品有限公司 微管溶素及蛋白质-微管溶素偶联物
BR112022024361A2 (pt) * 2020-06-24 2022-12-27 Regeneron Pharma Tubulisinas e conjugados de proteína-tubulisina
IL301702A (en) 2020-10-22 2023-05-01 Regeneron Pharma Anti-FGFR2 antibodies and methods of using them
US20220143194A1 (en) 2020-11-10 2022-05-12 Regeneron Pharmaceuticals, Inc. Selenium antibody conjugates
WO2023129518A1 (fr) 2021-12-29 2023-07-06 Regeneron Pharmaceuticals, Inc. Tubulysines et conjugués protéine-tubulysine
KR20250128394A (ko) 2022-11-30 2025-08-27 리제너론 파마슈티칼스 인코포레이티드 Tlr7 작용제 및 이의 항체-약물-접합체
WO2024235135A1 (fr) * 2023-05-12 2024-11-21 四川科伦博泰生物医药股份有限公司 Composé macrocyclique et son procédé de préparation et son utilisation
CN120981249A (zh) * 2023-05-12 2025-11-18 四川科伦博泰生物医药股份有限公司 多环化合物及其制备方法和用途
WO2025117727A1 (fr) 2023-11-29 2025-06-05 Regeneron Pharmaceuticals, Inc. Analogues d'agents cytotoxiques quinoxaline/quinoléine, conjugués lieur-agents, conjugués protéine-médicament et leurs utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008138561A1 (fr) * 2007-05-10 2008-11-20 R & D Biopharmaceuticals Gmbh Dérivés de tubulysine
WO2014126836A1 (fr) * 2013-02-14 2014-08-21 Bristol-Myers Squibb Company Composés de tubulysine, procédés d'élaboration et d'utilisation correspondants

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
EP1817341A2 (fr) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Anticorps et immunoconjugues mis au point
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (fr) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
EP2167963B1 (fr) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Supports polymères pour immunohistochimie et hybridation in situ
US8476451B2 (en) 2007-07-20 2013-07-02 The Regents Of The University Of California Tubulysin D analogues
WO2009012958A2 (fr) 2007-07-20 2009-01-29 Helmholtz-Zentrum für Infektionsforschung GmbH Analogues de la tubulysine d
AU2008316835B2 (en) 2007-10-25 2015-07-16 Endocyte, Inc. Tubulysins and processes for preparing
MX2010011808A (es) 2008-04-30 2011-03-04 Immunogen Inc Conjugados potentes y enlazadores hidrofilicos.
EP2174947A1 (fr) 2008-09-25 2010-04-14 Universität des Saarlandes Pré-tubulysines bioactives et leur utilisation
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
IT1394860B1 (it) * 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
WO2012005982A2 (fr) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Rapporteur pour une terminaison par la arn polymérase ii
EP2409983A1 (fr) 2010-07-19 2012-01-25 Leibniz-Institut für Pflanzenbiochemie (IPB) Analogues de la tubulysine
KR20140037105A (ko) 2011-05-27 2014-03-26 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EA029046B1 (ru) 2011-10-14 2018-02-28 Медимьюн Лимитед Пирролобензодиазепины и промежуточные соединения для их получения, способы их синтеза
CA2850373C (fr) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines et conjugues cibles
AU2012322613B2 (en) 2011-10-14 2016-04-21 Medimmune Limited Pyrrolobenzodiazepines and targeted conjugates
KR101891859B1 (ko) 2011-10-14 2018-08-24 메디뮨 리미티드 피롤로벤조디아제핀
WO2013068874A1 (fr) 2011-11-11 2013-05-16 Pfizer Inc. Conjugués anticorps-médicament
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9545449B2 (en) 2012-05-11 2017-01-17 Advanced Proteone Therapeutics Inc. Site-specific labeling and targeted delivery of proteins for the treatment of cancer
PT3210627T (pt) 2012-07-12 2023-03-23 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de ligação celular com agentes citotóxicos
HRP20230690T1 (hr) 2012-10-23 2023-10-13 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovo pripremanje
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
US20160022829A1 (en) 2013-03-14 2016-01-28 Mersana Therapeutics, Inc. Tubulysin compounds and conjugates thereof
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US11116847B2 (en) 2013-12-19 2021-09-14 Seagen Inc. Methylene carbamate linkers for use with targeted-drug conjugates
EP3099681B1 (fr) * 2014-01-28 2020-12-09 TUBE Pharmaceuticals GmbH Dérivés cytotoxiques de tubulysine et leurs conjugués
SG11201608203RA (en) 2014-04-11 2016-10-28 Medimmune Llc Tubulysin derivatives
KR20230172035A (ko) 2014-09-11 2023-12-21 씨젠 인크. 삼차 아민-함유 약물 물질의 표적화된 전달
US20170290878A1 (en) 2014-09-25 2017-10-12 Endocyte, Inc. Methods of treating cancer with tubulysin conjugates
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
WO2016089879A1 (fr) 2014-12-01 2016-06-09 Endocyte, Inc. Conjugués d'inhibiteurs de la garftase
JP6752204B2 (ja) 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド 四級アミン化合物及びその抗体−薬物コンジュゲート
JP2018509404A (ja) 2015-02-25 2018-04-05 ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ デスアセトキシツブリシンｈおよびその類似体
CA2978304A1 (fr) 2015-03-01 2016-09-09 Endocyte, Inc. Procedes de traitement du cancer avec un compose ligand du psma-tubulysine
WO2016168471A1 (fr) 2015-04-17 2016-10-20 Endocyte, Inc. Conjugués de médicaments à deux groupes disulfure
WO2017031209A1 (fr) 2015-08-18 2017-02-23 Endocyte, Inc. Analogues de tubulysine et procédés associés
PT3374398T (pt) 2015-11-10 2020-06-16 Medimmune Llc Moléculas de ligação específicas para asct2 e suas utilizações
WO2017134547A1 (fr) 2016-02-01 2017-08-10 Pfizer Inc. Analogues de la tubulysine et leurs procédés de préparation
SG11201806594QA (en) 2016-02-04 2018-09-27 Suzhou M Conj Biotech Co Ltd Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
EP3419670A2 (fr) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Conjugaison optimisée d'anticorps spécifique d'un site de transglutaminase
WO2017196598A1 (fr) 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Conjugués anticorps-médicaments d'analogues de la tubulysine à stabilité améliorée
SG11201900699QA (en) 2016-08-09 2019-02-27 Seattle Genetics Inc Drug conjugates with self-stabilizing linkers having improved physiochemical properties
MA46417A (fr) 2016-09-23 2019-07-31 Regeneron Pharma Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations
US20180125992A1 (en) * 2016-11-04 2018-05-10 Endocyte, Inc. Drug delivery conjugates of tertiary amine containing drugs
CN111601619A (zh) 2017-11-07 2020-08-28 里珍纳龙药品有限公司 用于抗体药物偶联物的亲水性连接体
CN111093707A (zh) 2017-12-31 2020-05-01 杭州多禧生物科技有限公司 含支链连接体的Tubulysin同系物偶联物
CN113454097B (zh) 2018-12-21 2024-08-30 里珍纳龙药品有限公司 微管溶素及蛋白质-微管溶素偶联物
EP3986476A4 (fr) 2019-06-24 2023-11-15 Hangzhou Dac Biotech Co., Ltd. Formulation d'un conjugué d'un analogue de tubulysine à une molécule de liaison cellulaire
MX2022010599A (es) * 2020-02-28 2022-09-09 Regeneron Pharma Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos.
BR112022024361A2 (pt) 2020-06-24 2022-12-27 Regeneron Pharma Tubulisinas e conjugados de proteína-tubulisina
IL301702A (en) * 2020-10-22 2023-05-01 Regeneron Pharma Anti-FGFR2 antibodies and methods of using them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008138561A1 (fr) * 2007-05-10 2008-11-20 R & D Biopharmaceuticals Gmbh Dérivés de tubulysine
WO2014126836A1 (fr) * 2013-02-14 2014-08-21 Bristol-Myers Squibb Company Composés de tubulysine, procédés d'élaboration et d'utilisation correspondants

Also Published As

Publication number Publication date
US12144864B2 (en) 2024-11-19
KR20210106467A (ko) 2021-08-30
US20210260208A1 (en) 2021-08-26
JP2024167209A (ja) 2024-12-03
SG11202106067UA (en) 2021-07-29
MA53765A1 (fr) 2022-02-28
MY208067A (en) 2025-04-11
JP2022516427A (ja) 2022-02-28
CN113454097B (zh) 2024-08-30
CN113454097A (zh) 2021-09-28
ZA202103867B (en) 2025-09-25
AU2019403554A1 (en) 2021-06-17
AU2019403554B2 (en) 2025-07-24
PH12021551421A1 (en) 2022-05-02
MX2021007235A (es) 2021-09-23
CL2024000459A1 (es) 2024-09-13
WO2020132658A2 (fr) 2020-06-25
CN118027137A (zh) 2024-05-14
CO2021009129A2 (es) 2021-07-30
EA202191769A1 (ru) 2021-12-08
WO2020132658A3 (fr) 2020-08-13
BR112021011729A2 (pt) 2021-11-09
CA3124106A1 (fr) 2020-06-25
IL283942A (en) 2021-07-29
CL2021001593A1 (es) 2022-01-21
JP7590328B2 (ja) 2024-11-26
EP3898651A2 (fr) 2021-10-27

Similar Documents

Publication Publication Date Title
MA53765B2 (fr) Tubulysines et conjugués tubulysines-protéines
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
AU2018338314A1 (en) Protein degraders and uses thereof
EP4603508A3 (fr) Anticorps anti-fzd et méthodes d'utilisation
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
MY208638A (en) Anti-steap1 antigen-binding protein
PH12022551105A1 (en) Tyk2 pseudokinase ligands
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
EP4428142A3 (fr) Dérivés de bis-octahydrophénanthrène carboxamide et conjugués de protéines de ceux-ci
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
WO2018067520A3 (fr) Procédés et agents thérapeutiques
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2024005705A (es) Composiciones de liquidos ionicos.
MX2022000712A (es) Moduladores de nlrp3.
WO2021207433A3 (fr) Épitopes d'anticorps neutralisant le sars-cov-2
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
WO2018183631A8 (fr) Nouvelles formulations pharmaceutiques contenant de l'indirubine et des dérivés de celui-ci et procédés de fabrication et d'utilisation de celles-ci
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
PH12022550277A1 (en) Biopharmacuetical compositions and related methods
PH12022551810A1 (en) Protein-antiviral compound conjugates